Compare · DXCM vs INFU
DXCM vs INFU
Side-by-side comparison of DexCom Inc. (DXCM) and InfuSystems Holdings Inc. (INFU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and INFU operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.08B, about 105.4x INFU ($294.9M).
- DXCM has been more active in the news (13 items in the past 4 weeks vs 8 for INFU).
- DXCM has more recent analyst coverage (25 ratings vs 3 for INFU).
- Company
- DexCom Inc.
- InfuSystems Holdings Inc.
- Price
- -
- -
- Market cap
- $31.08B
- $294.9M
- 1M return
- -5.08%
- -
- 1Y return
- +42.43%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2005
- News (4w)
- 13
- 8
- Recent ratings
- 25
- 3
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
InfuSystems Holdings Inc.
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) Services. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
Latest INFU
- InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by InfuSystems Holdings Inc.
- InfuSystems Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- InfuSystem Announces Financial Results for Third Quarter 2026
- InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- InfuSystem Announces Change in Third Quarter 2026 Earnings Release Date
- SEC Form 8-K filed by InfuSystems Holdings Inc.
- InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026
- SEC Form 4 filed by InfuSystems Holdings Inc.
- InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits